NMTR News and Press, 9 Meters Biopharma Inc. From 05/16/22

9 Meters Biopharma press release (NASDAQ:NMTR): Q1 GAAP EPS of -$0.04. Cash and cash equivalents of approximately $37.2M. The company anticipates its cash runway is sufficient to fund the ongoing clinical programs into the second quarter of 2023, including initiation of the Phase 3 vurolenati...

On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June Cash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023 RALEIGH, NC / AC...

RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will presen...

9 Meters Biopharma (NASDAQ:NMTR) said on Wednesday it had tied-up with Celiac.com, a website for gluten-free diet due to celiac disease, to help support clinical trial enrollment for its drug candidate larazotide to treat the gluten sensitivity disease. The drug is currently in late...

RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, and Celiac.com, a news, information, and support website for those on a gluten-...

9 Meters Biopharma (NASDAQ:NMTR) said the U.S. Patent and Trademark Office (USPTO) has allowed patent application No. 16/781,304, which provides protection for the use of NM-136 to treat hyperphagia (excessive hunger), serious metabolic conditions such as obesity, and for reducing fatty ...

RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark O...

9 Meters Biopharma press release (NASDAQ:NMTR): Q4 Non-GAAP EPS of -$0.04. As of December 31, 2021, the Company's cash and cash equivalents totaled approximately $47.0 million, compared to approximately $37.9 million as of December 31, 2020. For further details see: 9 Meters Biopharma N...

RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) , a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financ...

RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will pre...